Apathy and Volume of Tissue Activated (VTA) following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Cohort
Objective: To determine frequency and/or predictors of improvement or worsening of apathy, we evaluated this behavior among those who received bilateral subthalamic deep brain stimulation…Metabolic Biomarkers of Parkinson’s Disease in Peripheral Tissue
Objective: The goal of this study was to use magnetic resonance spectroscopy (MRS) to test whether muscles of individuals with Parkinson’s disease (PD) possess a…Differences between two cognitive assessment instruments used in Parkinson’s disease in Kyrgyzstan
Objective: The aim of this study was to determine differences between Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) in PD patients from Kyrgyzstan.…Parkinson’s patient insights, knowledge and experience of treatment – results from a multicountry survey
Objective: To understand the perceptions and knowledge that people with Parkinson’s disease (PD) have about their treatment, available options for advanced PD, and to determine…Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa
Objective: To evaluate time to ON without troublesome dyskinesia (‘good ON’) and patterns of motor-state stability throughout the day in patients with advanced Parkinson’s disease…Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)
Objective: To characterize the in vitro and in vivo pharmacologic profile of UCB0022 Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease with reductions in…Deep Brain Stimulation in Parkinson’s disease: Challenges of a young experience in southern Morocco
Objective: The objective of our research was to describe the epidemiological, therapeutic features and effectiveness of deep brain stimulation in operated patients. To cite the…CSF biomarkers in neurodegenerative parkinsonism can distinguish between multiple system atrophy and 4-repeat tauopathies, but not between disease with Lewy bodies and multiple system atrophy
Objective: To assess the usefulness of a defined set of blood-based and cerebrospinal fluid-based biomarkers in the differential diagnosis of neurodegenerative proteinopathies. Background: The diagnostic…An AAV9 encoding human ABCD1 (SBT101) shows functional improvement following spinal cord delivery in a rodent model of adrenomyeloneuropathy
Objective: SBT101 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy candidate delivering a functional copy of the human ABCD1 gene that is in development…The noradrenergic basis of Parkinson’s tremor
Objective: Study the effect of propranolol on (stress-related increase in) tremor power and on tremor-related activity in the cerebello-thalamo-cortical (CTC) circuit in Parkinson’s (PD) patients.…
- « Previous Page
- 1
- …
- 119
- 120
- 121
- 122
- 123
- …
- 153
- Next Page »